Codexis to Report Fourth Quarter and Fiscal Year 2023 Financial Results on February 28
February 14 2024 - 4:05PM
Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company,
today announced that it will report its financial results for the
fourth quarter and fiscal year 2023 on Wednesday, February 28,
2024, following the close of market. Codexis management will host a
conference call and webcast at 4:30 pm Eastern Time to discuss the
Company’s financial results and provide a business update.
Participants may access the live webcast on
the Codexis Investor Relations website, where it will be
archived for 90 days. The live call can be accessed by dialing
877-705-2976 (domestic) or 201-689-8798 (international). A
telephone replay of the call will be available for 48 hours by
dialing 877-660-6853 (domestic) or 201-612-7415 (international),
access ID #13726635.
About CodexisCodexis is a
leading enzyme engineering company leveraging its proprietary
CodeEvolver® technology platform to discover, develop and
enhance novel, high-performance enzymes and other classes of
proteins. Codexis enzymes solve for real-world challenges
associated with small molecule pharmaceuticals manufacturing and
nucleic acid synthesis. The Company is currently developing its
proprietary ECO Synthesis™ platform to enable the scaled
manufacture of RNAi therapeutics through an enzymatic route.
Codexis’ unique enzymes can drive improvements such as higher
yields, reduced energy usage and waste generation, improved
efficiency in manufacturing and greater sensitivity in genomic and
diagnostic applications. For more information,
visit www.codexis.com.
For More Information
Investor ContactCarrie McKim(336) 608-9706ir@codexis.com
Media ContactLauren Musto(650) 421-8205media@codexis.com
Codexis (NASDAQ:CDXS)
Historical Stock Chart
From Jun 2024 to Jul 2024
Codexis (NASDAQ:CDXS)
Historical Stock Chart
From Jul 2023 to Jul 2024